OncoMatch/Clinical Trials/NCT05679921

Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma

Is NCT05679921 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies pembrolizumab, pazopanib for soft tissue sarcoma.

Phase 2RecruitingYonsei UniversityNCT05679921Data as of Jun 2026Location: South Korea

Treatment: pembrolizumab, pazopanib — This is an open-label, randomized, phase II study to evaluate the clinical activity of pembrolizumab in combination with pazopanib compared to pazopanib monotherapy.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Targeted therapy

pembrolizumab, pazopanib

Cancer type

Sarcoma

Disease stage

Metastatic disease required

Performance status

ECOG 0–1(Restricted strenuous activity)

Demographics

Ages 20–80

Prior therapy

Max 2 prior lines

Min 1 prior line

Must have received: chemotherapy

progression to 1 or 2 (less than 3) prior chemotherapy

Cannot have received: Programmed Death-1 (PD-1) inhibitor

Any previous treatment with a Programmed Death-1(PD1) or Programmed Death-Ligand1(PD-L1) inhibitor, anti-PD-L2 agent, stimulatory/co-inhibitory T-cell receptor (eg. CTLA-4, OX-40, CD137), and/or pazopanib

Cannot have received: Programmed Death-Ligand 1 (PD-L1) inhibitor

Any previous treatment with a Programmed Death-1(PD1) or Programmed Death-Ligand1(PD-L1) inhibitor, anti-PD-L2 agent, stimulatory/co-inhibitory T-cell receptor (eg. CTLA-4, OX-40, CD137), and/or pazopanib

Cannot have received: Programmed Death-Ligand 2 (PD-L2) inhibitor

Any previous treatment with a Programmed Death-1(PD1) or Programmed Death-Ligand1(PD-L1) inhibitor, anti-PD-L2 agent, stimulatory/co-inhibitory T-cell receptor (eg. CTLA-4, OX-40, CD137), and/or pazopanib

Cannot have received: stimulatory/co-inhibitory T-cell receptor therapy

Any previous treatment with a Programmed Death-1(PD1) or Programmed Death-Ligand1(PD-L1) inhibitor, anti-PD-L2 agent, stimulatory/co-inhibitory T-cell receptor (eg. CTLA-4, OX-40, CD137), and/or pazopanib

Cannot have received: VEGFR inhibitor (pazopanib)

Any previous treatment with a Programmed Death-1(PD1) or Programmed Death-Ligand1(PD-L1) inhibitor, anti-PD-L2 agent, stimulatory/co-inhibitory T-cell receptor (eg. CTLA-4, OX-40, CD137), and/or pazopanib

Lab requirements

Blood counts

Hemoglobin ≥9.0 g/dL; ANC ≥ 1500/mm3; Platelet count ≥ 100,000/mm3

Kidney function

Creatinine ≤1.5 x ULN

Liver function

Serum bilirubin ≤1.5 x institutional ULN; AST/ALT ≤2.5 x ULN unless liver metastases are present, in which case ≤5x ULN

Adequate normal organ and marrow function as defined below -Hemoglobin ≥9.0 g/dL -Absolute neutrophil count (ANC) ≥ 1500 per mm3 -Platelet count ≥ 100,000 per mm3 -Serum bilirubin ≤1.5 x institutional upper limit of normal (ULN). -Aspartate Aminotransferase (AST, SGOT)/Alanine Aminotransferase (ALT, SGPT) ≤2.5 x institutional upper limit of normal unless liver metastases are present, in which case it must be ≤5x ULN -Creatinine≤1.5 x ULN

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT05679921 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior Programmed Death-1 (PD-1) inhibitor, Programmed Death-Ligand 1 (PD-L1) inhibitor, Programmed Death-Ligand 2 (PD-L2) inhibitor disqualifies patients from enrollment.

Is there an age limit?

Yes. Patients must be 80 years or younger and at least 20 years old.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify

Sarcoma trials